These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 37694572)
1. Advances and Challenges in the Development of Gene Therapy Medicinal Products for Rare Diseases. Bueren JA; Auricchio A Hum Gene Ther; 2023 Sep; 34(17-18):763-775. PubMed ID: 37694572 [TBL] [Abstract][Full Text] [Related]
2. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States. Iglesias-Lopez C; Obach M; Vallano A; Agustí A Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292 [TBL] [Abstract][Full Text] [Related]
3. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective. Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215 [TBL] [Abstract][Full Text] [Related]
4. Improving access to gene therapy for rare diseases. Fox TA; Booth C Dis Model Mech; 2024 Jun; 17(6):. PubMed ID: 38639083 [TBL] [Abstract][Full Text] [Related]
5. Regulatory Frameworks for Advanced Therapy Medicinal Products in Thailand. Boonprasirt P; Nimvorapun S; Sawangjang C; Poonpolsub S; Yoongthong W; Dunkum P Adv Exp Med Biol; 2023; 1430():221-233. PubMed ID: 37526851 [TBL] [Abstract][Full Text] [Related]
6. The Current State of Advanced Therapy Medicinal Products in the Czech Republic. Kočí Z; Boráň T; Krůpa P; Kubinová Š Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533 [TBL] [Abstract][Full Text] [Related]
7. Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspective. Tomeo F; Mariz S; Brunetta AL; Stoyanova-Beninska V; Penttila K; Magrelli A Br J Clin Pharmacol; 2021 Nov; 87(11):4183-4196. PubMed ID: 33772837 [TBL] [Abstract][Full Text] [Related]
8. The Relevance of Advanced Therapy Medicinal Products in the Field of Transplantation and the Need for Academic Research Access: Overcoming Bottlenecks and Claiming a New Time. Piemonti L; Scholz H; de Jongh D; Kerr-Conte J; van Apeldoorn A; Shaw JAM; Engelse MA; Bunnik E; Mühlemann M; Pal-Kutas K; Scott WE; Magalon J; Kugelmeier P; Berishvili E Transpl Int; 2023; 36():11633. PubMed ID: 37822447 [TBL] [Abstract][Full Text] [Related]
9. Advanced Therapy Medicinal Products for the Eye: Definitions and Regulatory Framework. López-Paniagua M; de la Mata A; Galindo S; Blázquez F; Calonge M; Nieto-Miguel T Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33800934 [TBL] [Abstract][Full Text] [Related]
10. 19th Annual Meeting of the Safety Pharmacology Society: regulatory and safety perspectives for advanced therapy medicinal products (cellular and gene therapy products). Cavero I; Seimetz D; Koziel D; Zimmermann WH; Holzgrefe HH Expert Opin Drug Saf; 2020 May; 19(5):553-558. PubMed ID: 32163309 [TBL] [Abstract][Full Text] [Related]
12. State-of-the-art knowledge on the regulation of advanced therapy medicinal products. Kidpun P; Ruanglertboon W; Chalongsuk R Per Med; 2022 May; 19(3):251-261. PubMed ID: 35293224 [TBL] [Abstract][Full Text] [Related]
13. Prospects of Advanced Therapy Medicinal Products-Based Therapies in Regenerative Dentistry: Current Status, Comparison with Global Trends in Medicine, and Future Perspectives. Bakopoulou A J Endod; 2020 Sep; 46(9S):S175-S188. PubMed ID: 32950189 [TBL] [Abstract][Full Text] [Related]
14. Realizing the Potential of Gene Therapies for Rare and Ultra-Rare Inherited Diseases. Booth C; Aiuti A Hum Gene Ther; 2023 Sep; 34(17-18):776-781. PubMed ID: 37624746 [TBL] [Abstract][Full Text] [Related]
15. Gene and cell therapy for children--new medicines, new challenges? Buckland KF; Bobby Gaspar H Adv Drug Deliv Rev; 2014 Jun; 73(100):162-9. PubMed ID: 24583376 [TBL] [Abstract][Full Text] [Related]
16. Licensing of Orphan Medicinal Products-Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021. Naumann-Winter F; Wolter F; Hermes U; Malikova E; Lilienthal N; Meier T; Kalland ME; Magrelli A Front Pharmacol; 2022; 13():920336. PubMed ID: 36034814 [No Abstract] [Full Text] [Related]
17. Call for More Effective Regulation of Clinical Trials with Advanced Therapy Medicinal Products Consisting of or Containing Genetically Modified Organisms in the European Union. Beattie S; Hum Gene Ther; 2021 Oct; 32(19-20):997-1003. PubMed ID: 33843251 [TBL] [Abstract][Full Text] [Related]
18. [Academic cell therapy facilities are challenged by European regulation on advanced therapy medicinal products]. Chabannon C; Sabatier F; Rial-Sebbag E; Calmels B; Veran J; Magalon G; Lemarie C; Mahalatchimy A Med Sci (Paris); 2014 May; 30(5):576-83. PubMed ID: 24939546 [TBL] [Abstract][Full Text] [Related]
19. Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products. Cuende N; Ciccocioppo R; Forte M; Galipeau J; Ikonomou L; Levine BL; Srivastava A; Zettler PJ Cytotherapy; 2022 Jul; 24(7):686-690. PubMed ID: 35545453 [TBL] [Abstract][Full Text] [Related]
20. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe. Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]